This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.68% per year. These returns cover a period from January 1, 1988 through August 5, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Zacks News
Allscripts' FollowMyHealth Partners Ephraim McDowell Health
by Zacks Equity Research
Allscripts' (MDRX) FollowMyHealth is an EHR-neutral patient engagement platform that allows patients to stay connected with their physicians.
Why Is AllScripts (MDRX) Down 17.1% Since Last Earnings Report?
by Zacks Equity Research
AllScripts (MDRX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Computer Systems & Jasper General Tie Up to Boost EHR Service
by Zacks Equity Research
Computer Systems (CPSI) sees a series of developments in the EHR platform.
Allscripts Partners With Opargo to Boost Practice Management
by Zacks Equity Research
Allscripts' (MDRX) partnership with Opargo is likely to improve scheduling capabilities and practice workflows of Allscripts Practice Management solution.
Allscripts Strengthens Strategic Relationship with Pulse8
by Zacks Equity Research
Pulse8 is likely to boost Allscripts' (MDRX) flagship platform Veradigm, and its existing health plan product suite that delivers pocket-friendly tools and services for health plan members.
Allscripts to Fortify Middle East Foothold With New Project
by Zacks Equity Research
Qatar-based Alfardan Group and Chicago-based Northwestern Medicine select Allscripts (MDRX) for the launch of a project in the Middle East.
Allscripts (MDRX) Q4 Earnings Lag Estimates, Bookings Up Y/Y
by Zacks Equity Research
Significant year-over-year rise in bookings favors Allscripts' (MDRX) fourth-quarter 2018 results.
AllScripts Healthcare (MDRX) Misses Q4 Earnings and Revenue Estimates
by Zacks Equity Research
AllScripts (MDRX) delivered earnings and revenue surprises of -4.76% and -4.53%, respectively, for the quarter ended December 2018. Do the numbers hold clues to what lies ahead for the stock?
AllScripts Healthcare (MDRX) Earnings Expected to Grow: Should You Buy?
by Zacks Equity Research
AllScripts (MDRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Allscripts (MDRX) Down 15.2% Since Last Earnings Report: Can It Rebound? (Revised)
by Zacks Equity Research
AllScripts (MDRX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Allscripts (MDRX) Misses Q3 Earnings and Revenue Estimates (Revised)
by Zacks Equity Research
Allscripts (MDRX) witnessed solid growth in Software delivery, Support and Maintenance and Client services segments in Q3.
Allscripts Selected by Premier for Connected Health Platform
by Zacks Equity Research
Premier Orthopaedics will leverage on Allscripts' (MDRX) Professional EHR, Practice Management software, FollowMyHealth and Payerpath suite of solutions.
Cerner (CERN) Teams Up With Nebraska-Based LRHC, Shares Up
by Zacks Equity Research
Cerner's (CERN) coveted Millennium platform has seen rising demand in recent times.
Allscripts (MDRX) Collaborates With Microsoft, Shares Up
by Zacks Equity Research
Allscripts' (MDRX) Veradigm unit signs a memorandum of understanding with Microsoft to develop an integrated research model.
Allscripts Healthcare (MDRX) Catches Eye: Stock Jumps 5.7%
by Zacks Equity Research
Allscripts Healthcare (MDRX) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.
Here's Why You Should Hold Allscripts Stock in Your Portfolio
by Zacks Equity Research
Allscripts (MDRX) has been winning contracts in the Sunrise EHR platform; competition stiff.
AllScripts (MDRX) Down 15.2% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
AllScripts (MDRX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Allscripts Healthcare Solutions (MDRX): Moving Average Crossover Alert
by Zacks Equity Research
Allscripts Healthcare Solutions, Inc. (MDRX) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front
Allscripts (MDRX) Misses Q3 Earnings and Revenue Estimates
by Zacks Equity Research
Significant margin contraction hurts Allscripts' (MDRX) results in Q3; decline in bookings discourages.
AllScripts Healthcare (MDRX) Q3 Earnings and Revenues Lag Estimates
by Zacks Equity Research
AllScripts (MDRX) delivered earnings and revenue surprises of -5.26% and -1.85%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
AllScripts Healthcare (MDRX) Q3 Earnings Preview: What to Expect
by Zacks Equity Research
AllScripts (MDRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Veeva Launches Vault SiteDocs for Regulatory Documentation
by Zacks Equity Research
Veeva's (VEEV) Vault SiteDocs Platform conducts high-quality, compliant clinical trials with greater visibility to researchers.
Cerner's Millennium Platform Integrated at McLaren Hospital
by Zacks Equity Research
Cerner's (CERN) Millennium HCIT platform sees a series of developments in 2018.
Here's Why You Should Hold on to athenahealth (ATHN) for Now
by Zacks Equity Research
athenahealth (ATHN) likely to gain from focus on cloud-based healthcare services.
Allscripts (MDRX) & Appriss Health Collaborate to Fight SUD
by Zacks Equity Research
Allscripts' (MDRX) EHR solutions have lucrative prospects.